NDANASALGEL, METERED
Approved
Nov 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
NASCOBAL (cyanocobalamin) by Accord Biopharma is clinical pharmacology vitamin b 12 is essential to growth, cell reproduction, hematopoiesis, and nucleoprotein and myelin synthesis. First approved in 1996.
Drug data last refreshed 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASCOBAL is a nasal gel formulation of cyanocobalamin (vitamin B12) approved in 1996 for treating vitamin B12 deficiency and associated cardiovascular conditions including coronary artery disease, myocardial infarction, and cerebrovascular stroke. The drug works by providing essential vitamin B12, which is critical for cell reproduction, hematopoiesis, and myelin synthesis. Cyanocobalamin is transported via binding proteins to tissues, with the liver serving as the primary storage organ.
$0.008BPart D
LOE ApproachingDeclining market opportunity with minimal Part D utilization (12 claims, $8K in 2023) signals a small, stable franchise with limited team expansion potential.
Mechanism of Action
CLINICAL PHARMACOLOGY Vitamin B 12 is essential to growth, cell reproduction, hematopoiesis, and nucleoprotein and myelin synthesis. Cyanocobalamin is quantitatively and rapidly absorbed from intramuscular and subcutaneous sites of injection; the plasma level of the compound reaches its peak within…
Worked on NASCOBAL at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.